Profiling histone post-translational modifications to identify signatures of epigenetic drug response in T-cell acute lymphoblastic leukemia
Laura CorveleyniD, Lien ProveziD, Osman Satilmis, Nina Refhagen, Mattias LandforsiD, Wouter SleeckxiD, Béatrice LintermansiD, A. De MaesschalckiD, Rishi Sury KotechaiD, Barbara De MoerlooseiD, Tim LammensiD, Dieter L. D. DeforceiD, Sofie DegermaniD, Steven GoossensiD, Pieter Van VlierbergheiD, Maarten DhaenensiD
Abstract
Epigenetic modifications are dynamic and reversible, making them attractive targets for therapeutic intervention in cancer. Although several epigenetic drugs (epidrugs) have been clinically approved, their application in T-cell acute lymphoblastic leukemia (T-ALL) remains limited, and predictive biomarkers of response are lacking. Here, we present a mass spectrometry (MS)-based pharmacoepigenetic approach to profile histone post-translational modifications (hPTMs) to identify signatures associated with epidrug sensitivity in T-ALL. Baseline hPTM landscapes were previously established by our group for 21 T-ALL cell lines using liquid chromatography-tandem mass spectrometry (LC-MS/MS). Here, we treated these cell lines with a panel of nine epidrugs including anthracyclines, histone deacetylase inhibitors, and DNA methyltransferase inhibitors. Correlation of cell viability data with hPTM levels revealed distinct hPTM signatures linked to sensitivity for each drug class. These signatures were subsequently evaluated in T-ALL patient-derived xenograft (PDX) models. However, we our analysis revealed substantial discepancies in hPTM sensitivity signatures compared to those observed in vitro. Co-variation network analysis highlighted divergence in hPTM-hPTM correlation between the two models, underscoring limitations of cell lines for modeling dynamic epigenetic regulation in vivo. Our findings establish a framework for MS-based hPTM profiling in T-ALL and emphasize the importance of model selection in developing predictive epigenetic biomarkers. Graphical abstract O_FIG O_LINKSMALLFIG WIDTH=200 HEIGHT=134 SRC="FIGDIR/small/673463v1_ufig1.gif" ALT="Figure 1"> View larger version (32K): org.highwire.dtl.DTLVardef@1b15092org.highwire.dtl.DTLVardef@20bed5org.highwire.dtl.DTLVardef@1d0a687org.highwire.dtl.DTLVardef@1652999_HPS_FORMAT_FIGEXP M_FIG C_FIG Global hPTM profiling of 21 T-ALL cell lines was performed using LC-MS/MS, as previously published by Provez et al. In parallel, the 21 cell lines were treated with a dilution series of nine epidrugs, categorized into three distinct classes, to determine their IC50 values. Finally, Spearman correlation analysis was performed to assess the relationship between hPTM levels and drug sensitivity. Figure created with Biorender.com.
02 /Specification & Classification
Click any tag to browse matching papers- Citations
- 1
- FWCI
- 2.05
- Field percentile
- top 16%
- Organism
- Assay
- Research Focus
- Approach
Reproducibility ledger
Nobody has reported trying to reproduce this paper yet. Did you replicate an experiment or run the code? Your report saves the next lab a week.
Sign in to file a reproducibility report.
Related papers
- An interactive mass spectrometry atlas of histone posttranslational modifications in T-cell acute leukemia
L. Provez, B. Van Puyvelde, … M. Dhaenens·bioRxiv·May 5, 2022
- PTEN-loss confers dependence on the guanylate synthesis enzyme IMPDH in T-cell acute lymphoblastic leukemia
Rayees Ahmad Padder, Thu Le Le, … Alexander J. Valvezan·bioRxiv·Dec 24, 2025
- Epigenetic inhibitors sensitize DLBCL cells to rituximab and doxorubicin
Chiara Facciotto, Julia Casado, … Sampsa Hautaniemi·bioRxiv·Feb 6, 2019
- Epigenetic reprogramming of plasmacytoid dendritic cells drives type I interferon-dependent differentiation of acute myeloid leukemias for therapeutic benefit
J. Salmon, I. Todorovski, … R. W. Johnstone·bioRxiv·Aug 23, 2020
- The pharmacoepigenomic landscape of cancer cell lines reveals the epigenetic component of drug sensitivity
A. J. Ohnmacht, A. Rajamani, … M. P. Menden·bioRxiv·Jun 1, 2023
- HDAC1 acts as tumor suppressor in ALK-positive anaplastic large-cell lymphoma: Implications for HDAC inhibitor therapy
Maša Zrimšek, Kristina Draganić, … Gerda Egger·LeukemiaPeer-reviewed·Apr 2, 2025